Treatment of Retinoblastoma in 2015: Agreement and Disagreement.

David H Abramson, Carol L Shields, Francis L Munier, Guillermo L Chantada

Journal: JAMA ophthalmology 2016;133(11):1341-7

PMID: 26378747

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

The management of intraocular retinoblastoma is rapidly changing, and even recent reviews on the subject are behind existing practices. The 4 authors of this report collectively represent their management strategies with an emphasis on areas of agreement and disagreement. Ophthalmic artery chemosurgery and intravitreous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90% without evidence of compromising patient survival.

Address: Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York2Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York.; Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.; Jules-Gonin Eye Hospital, Faculté de Biologie et Médecine de Lausanne, Lausanne, Switzerland.; Research Institute, Hospital J.P. Garrahan, Buenos Aires, Argentina.

DOI: 10.1001/jamaophthalmol.2015.3108

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Brachytherapy, Cryotherapy, Eye Enucleation, Humans, Infusions, Intra-Arterial, Intravitreal Injections, Laser Coagulation, Ophthalmic Artery, Retinal Neoplasms, Retinoblastoma